MedPath

Amphotericin B

Generic Name
Amphotericin B
Brand Names
Abelcet, Ambisome, Amphotec, Fungizone
Drug Type
Small Molecule
Chemical Formula
C47H73NO17
CAS Number
1397-89-3
Unique Ingredient Identifier
7XU7A7DROE
Background

Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphotericin B ranging from 0.03 to 1.0 mcg/mL in vitro. While Candida albicans is generally quite susceptible to amphotericin B, non-albicans species may be less susceptible. Pseudallescheria boydii and Fusarium sp. are often resistant to amphotericin B. The antibiotic is without effect on bacteria, rickettsiae, and viruses.

Indication

Used to treat potentially life threatening fungal infections.

Associated Conditions
Coccidioidomycosis, Fungal Infections, Histoplasmosis, Invasive Aspergillosis, Invasive Fungal Infections, Leishmaniasis, Meningitis, Cryptococcal, Meningitis, Fungal, Mucocutaneous Leishmaniasis, Mycotic endophthalmitis, Penicillium marneffei infection, Visceral Leishmaniasis, Candidal cystitis, Disseminated Cryptococcosis, Fungal osteoarticular infections, Ocular aspergillosis, Refractory aspergillosis, Severe Coccidioidomycosis, Severe Cryptococcosis, Severe Fungal infection caused by Basidiobolus spp., Severe Fungal infection caused by Conidiobolus spp., Severe Fungal infection caused by sporotrichosis spp., Severe Histoplasmosis, Severe Mucocutaneous leishmaniasis, Severe North American blastomycosis, Severe Systemic candidiasis
Clinical Trials
Related News

Five Novel 9-Month Oral Regimens Show Promise in Phase 3 Trial for Drug-Resistant TB

• Phase 3 endTB trial demonstrates that five all-oral 9-month regimens are as effective as standard 18-24 month treatment for rifampin-resistant tuberculosis, with four regimens proving noninferior. • New treatment combinations incorporating bedaquiline, clofazimine, levofloxacin, and pyrazinamide show favorable outcomes, though concerns about hepatotoxicity and peripheral neuropathy persist. • The successful trial highlights the importance of community-researcher trust, while emphasizing the need to address ongoing toxicity concerns in future treatment developments.

Matinas BioPharma's MAT2203 Shows Promise in Combating Severe Fungal Infections

• Matinas BioPharma's MAT2203, an oral formulation of amphotericin B, demonstrates enhanced survival and reduced fungal burden in preclinical studies. • The Phase 2 clinical trial drug aims to provide a safer, orally bioavailable treatment option for severe fungal infections, addressing toxicity concerns. • Matinas BioPharma utilizes its lipid-crystal nano-particle cochleate technology to improve drug delivery and efficacy of anti-infective therapies. • MAT2501, another candidate, is in Phase 1 trials targeting acute bacterial infections, including multi-drug resistant strains, using the same technology.

F2G Secures $100 Million to Advance Antifungal Olorofim After FDA Rejection

• F2G has raised $100 million to fund late-stage testing of olorofim, an antifungal drug intended to treat invasive aspergillosis, after initial FDA rejection. • The funding round was co-led by AMR Action Fund and ICG, with participation from eight other investors, signaling strong confidence in olorofim's potential. • Olorofim, an orotomide antifungal, targets a key enzyme in fungi and has received Breakthrough Therapy designation, with ongoing Phase 3 trials comparing it to AmBisome. • The investment will support completion of the Phase 3 trial, resubmission to the FDA, and preparations for the potential U.S. launch of olorofim.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy